Union Minister of State Jitendra Singh also gave credit to Prime Minister Narendra Modi for making this possible.

Covid-19: Govt Lauds ‘Team Biotech’ for World’s First Nasal Vaccine

Biotech Develops Worlds first Nasal Vaccine

Centre on Tuesday lauded Team Biotech for developing the world’s first Nasal Vaccine. ZyCoV-D, the world’s first and India’s indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above, was developed in partnership with the Department of Biotechnology (DBT) in the Ministry of Science & Technology under ‘Mission Covid Suraksha’ through BIRAC, a PSU of DBT.

Union Minister of State Jitendra Singh also gave credit to Prime Minister Narendra Modi for making this possible.

“PM Modi’s personal intervention and regular monitoring inspired and enabled the launching of “Mission Covid Suraksha” which has not only strengthened AtmaNirbhar Bharat but also bolstered India’s status as a worldwide vaccine development and manufacturing centre, thus showcasing the strength of India’s Science and Technology capabilities. It is a moment of great pride for every Indian,” he added.

He said that the product development and clinical trials were funded by the Department of Biotechnology and BIRAC under “Mission Covid Suraksha”. This vaccine received approval under restricted use in emergency situations for ages 18 and above for primary two-dose schedule, homologous booster doses, he added.

National Institute of Immunology (NII) New Delhi, an autonomous institute under the Department of Biotechnology utilised its “Human Immune Monitoring and T-cell Immunoassay Platform” to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses in the trial participants.

Interactive Research School for Health Affairs (IRSHA), Pune (supported by DBT BIRAC) completed the “Plaque Reduction Neutralization Assay” (PRNT) to quantify the titer of neutralising antibodies for the virus from three trial sites.

The vaccine is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results. It has been specifically formulated to allow intranasal delivery through nasal drops. The vaccine is stable at 2-8°C for easy storage and distribution.

Also Read:- Country’s First ‘One Health’ Consortium Launched By D/o Biotechnology, Post COVID 19
Facebook Comments